SystImmune
百利天恒
elsewhere's corpus does not cover SystImmune — the retrieved material contains no substantive reporting on the company, so there's nothing here to profile it from. If you're interested in Qiming Venture Partners' portfolio companies more broadly, the results below do cover several of them.
AI-generated — may contain errors, please verify.
SystImmuneCompany
百利天恒
No graph yet
Mentioned in 3 articles
Coverage
BlueRun Ventures in Conversation with QUA Biotech, AllinkBio, and Zenitar: Breaking Out of the Red Sea — The "Value" Evolution of China's Innovative Drugs
The Leap from "Imitation and Followership" to "Original Innovation"
Qiming Perspective | Qiming Venture Partners' Kan Chen: China's Innovative Drug Exports Hit Record Highs, Where Is Innovative Drug Investment Heading?
Beyond its homegrown efficiency advantages, China's biotech sector must also seize the opportunities presented by global collaborative clinical development in the years ahead — leveraging strengths across different regions worldwide to maximize biotech value creation.
10 Facts About 1,000 Chinese Billionaires
The currents of the era, all contained within the sequence.
